UNASSIGNED: Type 2 @entity6 (T2D) alters capillary hemodynamics, causes capillary rarefaction in skeletal muscle and alters endothelial and vascular smooth muscle cell phenotype. These changes contribute to altered blood flow responses to physiological stimuli such as; exercise and @entity2690 secretion. T2D-induced @entity409 impairs @entity413 and @entity2690 delivery to skeletal muscle (and other tissues such as skin and nervous), thereby reducing @entity413 uptake and perpetuating @entity4854 and hypersinsulinemia. In @entity1 with T2D, exercise training (EX) improves microvascular vasodilator and @entity2690 signaling, and attenuates capillary rarefaction in skeletal muscle. EX-induced changes augment @entity413 / @entity2690 delivery and @entity413 uptake. If these adaptions occur in a sufficient amount of tissue, and skeletal muscle in particular, chronic exposure to @entity4854 and @entity3190 , and as the risk of microvascular complications in all vascular beds will decrease. We postulate that EX-programs that engage as much skeletal muscle mass, and recruit as many muscle fibers within each muscle, as possible will generate the greatest improvements in microvascular function, providing the duration of the stimulus is sufficient. Primary improvements in microvascular function occur in tissues (skeletal muscle primarily) engaged during exercise and secondary improvements in microvascular function throughout the body may result from improved blood @entity413 control. We propose that the added benefit of combined resistance and aerobic EX programs and of vigorous intensity EX programs is not simply "more is better". Rather, the additional benefit is the result of EX-induced adaptations in and around more muscle fibers, resulting in more muscle mass, and the associated microvasculature, being changed.

Endurance vs. interval sprint training and/or resistance training; impact on XXXX in type 2 @entity6 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity409 :: ('MESH:D008107', 'Disease') :: ['microvascular dysfunction'] @entity2690 :: ('3630', 'Gene') :: ['insulin'] @entity3190 :: ('MESH:D006946', 'Disease') :: ['hyperinsulinemia'] @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity409 :: (MESH:D008107,Disease) :: ['microvascular dysfunction']
